Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Hi. Basically for a treatment to have "value" it has to be proven and the first step is "proof of concept".Effectively that means it is feasible for use in the real world and therefore has real value and good potential. As I understand it the news today means that Reneuron are the first company who have managed to breach the blood/brain barrier with little or no loss of potency/efficacy to the "treatment". If the progress in development continues this means a possible unlimited potential to apply their delivery method to a vast range of conditions!Thus we should now see numerous licensing deals being proposed which hopefully will be worth hign values.If the RP treatment also proves positive with the next updates we are looking at VERY good times indeed....and well worth the (long!!) wait!!!
Looks like we were all wrong.Latest update is all approvals received and all patients expected to be treated by end 2021. However,re efficacy results "the Company now expects to present early efficacy data on the expansion cohort in Q1 2022". I guess the share price will take another dive now...could be time to scrape some money together and "buy the dip".
Hi Chester. Thanks for the info.Just to clarify I took my info from the Reneuron site Clinical Trials section and whilst the company issued statements on 8th July 2021 the last available update on data for the original patients was Nov 2020 -"In June 2020 (and updated in November 2020), subsequent long-term efficacy data from the study continued to show a meaningful clinical effect from the therapy at all time points out to twelve months post-treatment". Thus no updates on those patients for nearly a year and it would be interesting to know how the treatment is faring all these months later (better/worse/as expected).
Re the expanded trials, OH stated n the Annual Report and Accounts referring to the regulatory approval for UK/Spain "It is anticipated that this process will conclude in August and if so this would allow dosing to resume in all three territories". AGM was September but there has been no update as to whether they met the target of August for the UK/Spain trial sites so at present all we know is the USA is recruiting/carrying out trials after receipt of relevant authorisations.I get the impression reporting of 3 month data for that trial is an aspiration not a definite.
With Reneuron's track record on reporting I think December would be more likely for the next update,although an update with good news in October would be most welcome.
Agree completely.What I find extremely disappointing is the lack of update regarding original RP trials.How are those patients faring?Has the treatment held up over time or would they be looking at additional dosage/treatments?Or maybe there has been further improvement? All we know is there is nothing "negative" to report.Last update was Nov 2020 so surely there must be more data by now? Also,we are promised data from the USA trials of the increased dosage by y/e 2021 but have not been updated re those trial restarts for Europe-expected restart by end of Aug. Have they recommenced those trials or not?
When you read the glossy brochure it mentions "proof of concept".RP is a potential "proof of concept" treatment that would really launch this company if approved. Loads of positive vibes relating to the science and from the board regarding hopes for the next 15 months or so but definitely lacking in hard data and updates! We can only hope the board know how good their product will be and are not prepared to "sell at any price" but will wait for true value once they release more data. Question is WHEN?? I am holding on as I feel very positive yet despair at the drop in share price...even though we know "smart money" has been invested in this share! With any luck a very happy Xmas???
Within the last couple of years Reneuron conducted "cost saving" project then carried out a rights issue to raise funds. We have seen an additional broker brought in then strong appointments to the board plus top scientic personnel being involved. Company has Fosun for Asia and added board expertise relating to USA and European markets,which I think speaks volumes regarding intentions and expectations.To me O H seems like the schoolkid with a secret they cannot reveal but are bursting to let everyone know!The last update seemed to be strong in terms of when and what was expected over the following 18 months or so.There are shrewd investors who have bought large volumes of shares which should be a serious hint as to the potential of the company......and yet the price is dropping? Now showing as 100p ASK!! Whilst there has been no news that in itself is good and the last report was "nothing negative" regarding the patients who had received treatment many months ago. I am hopeful of really positive news by year-end with a corresponding increase in share price.I had not intended increasing my holding but at this price I could not resist.Managed to buy at 99p. I will be patient but looking forward to the next 6 to 12 months and still hopeful of a big future for Reneuron and thier exosome product(s). Then again,maybe I am misreading the signs?
Hi.First time posting so firstly thanks to all those who post useful,thoughtful comments.Personally I think we have too many "speculators" and not enough "investors" in this company. I hold onto my shares as I believe in their science/products and am confident Reneuron has a very bright future ahead.
My question to Allenby. Which companies do you refer to regarding bankruptcies? Ms. Staehelin is listed by Reneuron with 3 prior roles. Keires AG is an ongoing concern a far as I can ascertain. GetWellness AG went into solvent liquidation so not bankrupt,they simply decided to cease trading and take any profits. Finally,SIRS-Lab GmbH. This company actually thrived until after she left.She was appointed turnaround CEO and over 3 years oversaw capital raising,successful clinical trials and decided to leave,but with the company in an obvious better position than when she arrived!The reason for liquidation,as far as I can ascertain,is the inability of shareholders and investors to agree on funding to take their product to market,but the inference was that under her stewardship they had actually thrived so I do not think you can blame her if the company was liquidated (Nov 2013) after she had resigned (July 2012).
If there are other companies that Reneuron did not list could you enlighten up please? From the details Reneuron posted I would be extremely pleased to have her on the board. The recent appointments and news are very upbeat and make me think Reneuron are expecting big things over the next 12 months. I simply cannot understand why the market sentiment is so negative,but then as mentioned I think we have too many "speculators"!